Reply To: Traders Market Weekly: Geopolitics, ECB and Apple


3D Systems Announces Formation of New Biotech Company, Systemic Bio™, to Accelerate Drug Discovery and Development

New company will leverage 3D Systems’ recent breakthroughs in bioprinting of vascularized human organs and tissues to accelerate new drug development, reduce costs, and ultimately reduce or eliminate the need for animal testing
Unique bioprinted organ-on-a-chip platform, h-VIOS™, created using hydrogels to produce complex vasculature that supports extended life in healthy or diseased human cells for use in drug studies
3D Systems to provide $15 million in seed funding to demonstrate efficacy of technology and business model, with targeted revenues of Systemic Bio approaching $100 million annually within five years
Taci Pereira named Chief Executive Officer of Systemic Bio, bringing deep expertise in bioengineering and bioprinting